Related Experiment Videos
[Clinical study of fluconazole-injectable and -granules in pediatric patients]
1Department of Pediatrics, School of Medicine, Kanazawa University.
Abstract:
In this study, we have investigated the clinical effectiveness of fluconazole (FLCZ) given intravenously or orally to pediatric patients with systemic fungal infections. FLCZ was administered intravenously to two patients with acute leukemia (multiple hepatosplenic candidiasis and aspergillosis) and orally to two mycosis complicated with neuroblastoma and aplastic anemia, respectively. Clinical efficacies were excellent and no side effects were observed in any patients. Pharmacokinetic analysis in 6 neonates revealed that the plasma half-life is 37-41 hours after administration of single dose of intravenous infusion of 3 mg/kg of FLCZ.
Insights
This study shows fluconazole (FLCZ) is effective for pediatric systemic fungal infections, with excellent clinical outcomes and no side effects observed in patients. Pharmacokinetic data in neonates indicates a long plasma half-life for FLCZ.
Area of Science:
- Pediatric Mycology
- Clinical Pharmacology
- Antifungal Therapeutics
Background:
- Systemic fungal infections pose a significant threat to immunocompromised pediatric patients.
- Fluconazole (FLCZ) is a widely used antifungal agent, but its efficacy and safety in pediatric populations require ongoing investigation.
- Treatment strategies for pediatric fungal infections often involve careful consideration of administration routes and pharmacokinetic profiles.
Observation:
- The study evaluated the clinical effectiveness of intravenous and oral fluconazole (FLCZ) in four pediatric patients with severe systemic fungal infections.
- Two patients with acute leukemia received intravenous FLCZ for candidiasis and aspergillosis.
- Two patients with neuroblastoma and aplastic anemia, respectively, received oral FLCZ for complicated mycosis.
Findings:
- Excellent clinical efficacy was observed in all treated pediatric patients.
- No adverse side effects were reported during the administration of fluconazole.
- Pharmacokinetic analysis in six neonates demonstrated a plasma half-life of 37-41 hours following a single intravenous dose of 3 mg/kg FLCZ.
Implications:
- Intravenous and oral fluconazole (FLCZ) represent a safe and effective treatment option for systemic fungal infections in pediatric patients.
- The prolonged plasma half-life of FLCZ in neonates suggests potential for optimized dosing regimens in this vulnerable population.
- Further research into FLCZ pharmacokinetics and pharmacodynamics in diverse pediatric subgroups is warranted to refine treatment protocols.